Trials / Recruiting
RecruitingNCT07473167
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
A Multi-center, Single Arm, Open-label Phase 1/2 Clinical Trial to Evaluate Safety, and to Explore Efficacy of TC011(CD19 Targeted CAR-T) in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 98 (estimated)
- Sponsor
- TICAROS Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.
Conditions
- Relapsed Large B-cell Lymphoma
- Refractory Large B-cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- High-grade B-cell Lymphoma (HGBL)
- Transformed Follicular Lymphoma (TFL)
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TC011 | Anti-CD19 Chimeric Antigen Receptor T cell |
Timeline
- Start date
- 2023-08-03
- Primary completion
- 2028-02-11
- Completion
- 2028-03-10
- First posted
- 2026-03-16
- Last updated
- 2026-03-16
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07473167. Inclusion in this directory is not an endorsement.